WAY 120491: RN given refers to the (3S-trans)-isomer; RN for cpd without isomeric designation not available 3/91 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 130292 |
| CHEMBL ID | 279392 |
| SCHEMBL ID | 4254850 |
| MeSH ID | M0184761 |
| Synonym |
|---|
| 124916-54-7 |
| way 120491 |
| unii-018nme21ed |
| way-120,491 |
| 1h-isoindol-1-one, 2-(3,4-dihydro-3-hydroxy-2,2-dimethyl-6-(trifluoromethoxy)-2h-1-benzopyran-4-yl)-2,3-dihydro-, (3s-trans)- |
| 2-(3,4-dihydro-3-hydroxy-2,2-dimethyl-6-(trifluoromethoxy)-2h-1-benzopyran-4-yl)-2,3-dihydro-1h-isoindol-1-one |
| 018nme21ed , |
| celikalim |
| CHEMBL279392 |
| 2-[(3s,4r)-3-hydroxy-2,2-dimethyl-6-(trifluoromethoxy)-3,4-dihydrochromen-4-yl]-3h-isoindol-1-one |
| SCHEMBL4254850 |
| way-120491 |
| (-)-(3s-trans)-2-(3,4-dihydro-3-hydroxy-2,2-dimethyl-6-(trifluoromethoxy)-2h-1-benzopyran-4-yl)-2,3-dihydro-1h-isoindol-1-one |
| 1h-isoindol-1-one, 2-((3s,4r)-3,4-dihydro-3-hydroxy-2,2-dimethyl-6-(trifluoromethoxy)-2h-1-benzopyran-4-yl)-2,3-dihydro- |
| DTXSID90924963 |
| 2-[3-hydroxy-2,2-dimethyl-6-(trifluoromethoxy)-3,4-dihydro-2h-1-benzopyran-4-yl]-2,3-dihydro-1h-isoindol-1-one |
| 2-[3-hydroxy-2,2-dimethyl-6-(trifluoromethoxy)-3,4-dihydrochromen-4-yl]-3h-isoindol-1-one |
| 2-((3s,4r)-3-hydroxy-2,2-dimethyl-6-(trifluoromethoxy)chroman-4-yl)isoindolin-1-one |
| zoratyfutxfljs-sjorkvtesa-n |
| AKOS040754398 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID179773 | In vitro inhibitory concentration that relaxed KCL induced contraction in rat detrusor strip by 50% | 2000 | Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6 | Design and SAR of novel potassium channel openers targeted for urge urinary incontinence. 2. Selective and potent benzylamino cyclobutenediones. |
| AID178736 | Effective dose in vivo for reduction in the frequency of spontaneous bladder contractions in the rat oral administration | 2000 | Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6 | Design and SAR of novel potassium channel openers targeted for urge urinary incontinence. 1. N-Cyanoguanidine bioisosteres possessing in vivo bladder selectivity. |
| AID173812 | Effective dose in vivo for reduction in MAP in normotensive rat model after oral administration | 2000 | Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6 | Design and SAR of novel potassium channel openers targeted for urge urinary incontinence. 1. N-Cyanoguanidine bioisosteres possessing in vivo bladder selectivity. |
| AID232709 | Selectivity ratio of MAP ED20/bladder ED50 | 2000 | Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6 | Design and SAR of novel potassium channel openers targeted for urge urinary incontinence. 2. Selective and potent benzylamino cyclobutenediones. |
| AID179774 | In vitro inhibitory concentration that relaxes KCL induced contraction in rat detrusor strips by 50% | 2000 | Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6 | Design and SAR of novel potassium channel openers targeted for urge urinary incontinence. 1. N-Cyanoguanidine bioisosteres possessing in vivo bladder selectivity. |
| AID173807 | Compound was evaluated in vivo for the effective dose that cause a 20% drop in MAP normotensive rat after oral administration | 2000 | Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6 | Design and SAR of novel potassium channel openers targeted for urge urinary incontinence. 2. Selective and potent benzylamino cyclobutenediones. |
| AID177812 | Compound was evaluated in vivo for the effective dose that cause a 50% reduction in frequency of spontaneous bladder contraction in the rat hypertrophied model after oral administration | 2000 | Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6 | Design and SAR of novel potassium channel openers targeted for urge urinary incontinence. 2. Selective and potent benzylamino cyclobutenediones. |
| AID232708 | Selectivity ratio of MAP ED20/bladder ED50 | 2000 | Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6 | Design and SAR of novel potassium channel openers targeted for urge urinary incontinence. 1. N-Cyanoguanidine bioisosteres possessing in vivo bladder selectivity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (72.73) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.96) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||